This exploratory study provides the first in vivo proof of concept that targeting gC1qR at the C1q binding site can significantly reduce mesothelioma tumor burden by increasing tumor cell apoptosis and decreasing tumor angiogenesis. This evidence concerns the gene C1QBP and neoplasm.